This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Buy Orthofix (OFIX) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market
by Zacks Equity Research
Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.
Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 102.99% and 1.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Advances in ALIF Procedure With New Launch
by Zacks Equity Research
Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 50% and 3.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.
Here's Why You Should Retain Amedisys (AMED) Stock for Now
by Zacks Equity Research
Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.
Why You Should Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry and the S&P 500 due to impressive quarterly results and segmental prospects.
Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips
by Zacks Equity Research
Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.
Orthofix (OFIX) Progresses With Limb-Lengthening Device
by Zacks Equity Research
Orthofix's (OFIX) Fitbone TAA intramedullary limb-lengthening system is implanted through a minimally invasive procedure.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.
Amedisys (AMED) Faces Macro Challenges, Margin Pressure
by Zacks Equity Research
The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.
Teleflex (TFX) OEM Arm Grows, Supply Issue Persists
by Zacks Equity Research
From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.
Globus Medical (GMED) Global Growth Strong Despite Margin Woe
by Zacks Equity Research
Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.
Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue
by Zacks Equity Research
Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.
Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.
Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth
by Zacks Equity Research
Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX), led by the continued strength of the GYN Surgical business.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.
Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise
by Zacks Equity Research
Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.
Abbott (ABT) to Upgrade PHCs Across India With New Pact
by Zacks Equity Research
Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.
Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues
by Zacks Equity Research
Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.
SmileDirectClub (SDC) Gains From Innovation Amid Macro Issues
by Zacks Equity Research
A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives for SmileDirectClub (SDC).